肺癌患者化疗前后外周血sPD-L1变化及其临床意义  

Change and significance of soluble PD-L1 before and after chemotherapy in patients with lung cancer

作　　者：王晓景[1] 施敏骅[1] 陈永井[2] 

机构地区：[1]苏州大学附属第二医院呼吸病科,江苏省215006 [2]苏州大学生物技术研究所

出　　处：《江苏医药》2013年第6期654-657,共4页Jiangsu Medical Journal

基　　金：国家自然科学青年基金(30800997);国家自然科学基金(81272610);苏州市社会发展科技项目(SZD0877);苏州市科技发展计划项目(YJS0925)

摘　　要：目的探讨肺癌患者化疗前后血清中可溶性程序性死亡配体1(sPD-L1)的表达变化及其临床意义。方法采用ELISA检测肺癌患者40例(肺癌组)、肺部良性疾病患者40例(良性组)和健康体检者40例(对照组)血清sPD-L1的动态变化,分析sPD-L1表达与TNM分期、功能状态(PS)评分、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)及细胞角蛋白19血清片段211(CYFRA211)的相关性。结果肺癌组sPD-L1水平高于良性组和对照组(P<0.05和P<0.01)。达客观缓解的肺癌患者,化疗后血清sPD-L1水平比化疗前显著降低(P<0.01);疾病进展的肺癌患者化疗后sPD-L1水平比化疗前显著升高(P<0.01)。肺癌患者sPD-L1异常高表达与PS评分、淋巴结转移密切相关(P<0.05)。血清sPD-L1表达与肿瘤标志物CEA、CYFRA211及NSE密切相关。结论肺癌患者外周血清sPD-L1的表达异常增高,且与肺癌的分期、转移和疗效密切相关。Objective To investigate the change and significance of serum soluble programmed death-1 ligand 1 （sPD-L1） before and after chemotherapy in the patients with lung cancer. MethodsSerum sPD-L1 protein expression was detected by ELISA kit in 40 patients with lung cancer（group A） ,40 cases with benign pulmonary diseases （group B） and 40 healthy volunteers （group C）. Therelationship of serum sPD-L1 with TNM staging, PS score as well as cancer embryo antigen（CEA）, neuron specific enolase （NSE） and cytokeratin 19 serum fragment 211 （CYFRA211 ） was analyzed.Results The expression of sPD-L1 in group A was significantly higher than that in groups of B and C （P〈0. 05 and P〈0. 01）. Compared to before, serum sPD-L1 expression after chemotherapy wassignificantly lower in lung cancer patients with objective remission（P〈0. 01）, but was higher in those with progression disease（P〈0. 01）. High expression of sPD-L1 in lung cancer patients was closelycorrelated to PS and lymph node and distant metastasis（P〈0. 05）. Serum sPD-L1 expression was closely related to serum levels of CEA, CYFRA211 and NSE. Conclusion Abnormally overexpressionof serum sPD-L1 is found in lung cancer patients, which is closely related with lung cancer staging, metastasis and response to chemotherapy.

关 键 词：肺癌 可溶性程序性死亡配体1 

分 类 号：R734[医药卫生—肿瘤]